Real-world effectiveness of NALIRIFOX versus modified FOLFIRINOX or gemcitabine and nab-paclitaxel in first-line advanced pancreatic adenocarcinoma: a multicentre propensity-matched study
BMJ Oncology · 2026-07 · 5 (2) · e001085
DOI: 10.1136/bmjonc-2026-001085 ↗Kurz gefasst
Fachartikel in der Zeitschrift BMJ Oncology, online erschienen am 03.07.2026. Verfasst von Tawasapon Thambamroong und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Medicine, Phramongkutklao Hospital, Bangkok, Thailand. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Thai Society of Clinical Oncology.
Abstract (Originalsprache)
Objective
To compare the real-world effectiveness and recorded safety of first-line liposomal irinotecan+oxaliplatin+fluorouracil+leucovorin (NALIRIFOX), modified FOLFIRINOX (mFOLFIRINOX) and gemcitabine plus nab-paclitaxel (Gem/NabP) in treatment-naïve patients with advanced pancreatic ductal adenocarcinoma (PDAC) in Thailand. Methods and analysis This retrospective, multicentre cohort study included adult patients with unresectable locally advanced or metastatic PDAC who initiated first-line NALIRIFOX, mFOLFIRINOX or Gem/NabP across 10 major Thai cancer centres between January 2021 and July 2024. Propensity score matching was performed to reduce treatment selection bias using age, sex, Eastern Cooperative Oncology Group performance status, metastatic burden, primary tumour location and baseline albumin. Overall survival (OS) and progression-free survival (PFS) were the primary outcomes. Secondary outcomes were objective response rate (ORR) and grade ≥3 treatment-related adverse events. Safety analyses were limited to matched patients with sufficient follow-up documentation to assess toxicity retrospectively.
Results
Of 513 eligible patients, 199 were included in the matched cohort: 52 received NALIRIFOX, 105 mFOLFIRINOX and 42 Gem/NabP. Median OS was 10.4 months for NALIRIFOX, 9.6 months for mFOLFIRINOX and 6.0 months for Gem/NabP. NALIRIFOX was associated with similar OS to mFOLFIRINOX (HR 1.09, 95% CI 0.72 to 1.67; p=0.68) and longer OS than Gem/NabP (HR 1.68, 95% CI 1.03 to 2.75; p=0.04). Median PFS was 5.0 months for both NALIRIFOX and mFOLFIRINOX and 4.3 months for Gem/NabP; NALIRIFOX showed longer PFS than Gem/NabP (HR 1.63, 95% CI 1.05 to 2.50; p=0.03), while PFS was similar between NALIRIFOX and mFOLFIRINOX. ORR was 37.5% for NALIRIFOX, 23.8% for mFOLFIRINOX and 40.5% for Gem/NabP. Recorded grade ≥3 toxicities appeared lower with NALIRIFOX, although cross-regimen safety comparisons were limited by retrospective toxicity ascertainment and likely differential reporting. Baseline carbohydrate antigen 19-9 remained imbalanced after matching because it was not included in the propensity model.
Conclusion
In this multicentre real-world matched cohort of advanced PDAC, NALIRIFOX and mFOLFIRINOX were associated with comparable survival outcomes, and both were associated with more favourable survival than Gem/NabP. Recorded grade ≥3 toxicities appeared lower with NALIRIFOX, but safety findings should be interpreted cautiously because of retrospective toxicity capture and residual confounding. Prospective studies are needed to validate these findings.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Medical Oncology, Department of Medicine, Phramongkutklao Hospital, Bangkok, Thailand.
- Division of Medical Oncology, Department of Medicine, Phramongkutklao College of Medicine, Bangkok, Thailand.
- Department of Medicine, Chaophya Abhaibhubejhr Hospital, Mueang Prachin Buri District, Thailand.
- Division of Medical Oncology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
- Division of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
- Division of Medical Oncology, Department of Medicine, Chulalongkorn University Faculty of Medicine, Bangkok, Thailand.
ORCID-Profile: Tawasapon Thambamroong, Nuttapong Ngamphaiboon, Chanchai Charonpongsuntorn
Förderung
- Thai Society of Clinical Oncology
Zitieren
APA
Thambamroong, T., Meesart, R., Prasongsook, N., Ngamphaiboon, N., Akewanlop, C., Tanasanvimon, S., Phavirunsiri, J., Pakvisal, N., Korphaisarn, K., Sathitruangsak, C., Siripoon, T., Simseekeaw, P., Charonpongsuntorn, C., Wirasorn, K., Kerkarchachai, G., Eiamprapaporn, P., Suksombooncharoen, T., Sa-Nguansai, S., Patiluntakankul, A., & Sirachainan, E. (2026). Real-world effectiveness of NALIRIFOX versus modified FOLFIRINOX or gemcitabine and nab-paclitaxel in first-line advanced pancreatic adenocarcinoma: a multicentre propensity-matched study. BMJ Oncology, 5(2), e001085. https://doi.org/10.1136/bmjonc-2026-001085
Vancouver
Thambamroong T, Meesart R, Prasongsook N, Ngamphaiboon N, Akewanlop C, Tanasanvimon S, et al. Real-world effectiveness of NALIRIFOX versus modified FOLFIRINOX or gemcitabine and nab-paclitaxel in first-line advanced pancreatic adenocarcinoma: a multicentre propensity-matched study. BMJ Oncology. 2026;5(2):e001085. doi:10.1136/bmjonc-2026-001085
BibTeX
@article{Thambamroong2026,
author = {Thambamroong, Tawasapon and Meesart, Ratchadakorn and Prasongsook, Naiyarat and Ngamphaiboon, Nuttapong and Akewanlop, Charuwan and Tanasanvimon, Suebpong and Phavirunsiri, Jarearnjit and Pakvisal, Nussara and Korphaisarn, Krittiya and Sathitruangsak, Chirawadee and Siripoon, Teerada and Simseekeaw, Pronwasun and Charonpongsuntorn, Chanchai and Wirasorn, Kosin and Kerkarchachai, Gorawich and Eiamprapaporn, Panuch and Suksombooncharoen, Thatthan and Sa-Nguansai, Sunatee and Patiluntakankul, Alan and Sirachainan, Ekaphop},
title = {Real-world effectiveness of NALIRIFOX versus modified FOLFIRINOX or gemcitabine and nab-paclitaxel in first-line advanced pancreatic adenocarcinoma: a multicentre propensity-matched study},
journal = {BMJ Oncology},
year = {2026},
volume = {5},
number = {2},
pages = {e001085},
doi = {10.1136/bmjonc-2026-001085}
}
EUVIMED